Bedtime Device Restriction and Desmopressin in PMNE.

This randomized controlled trial will evaluate whether restricting bedtime digital-device use improves the response to desmopressin in children with primary monosymptomatic nocturnal enuresis. Participants will receive desmopressin for 8 weeks and will be assigned to either bedtime device restriction or usual screen habits.

Inclusion Criteria: * Age 6-14 years. * Diagnosis of PMNE (≥2 wet nights/week for ≥6 months, no daytime symptoms, no prior sustained dryness \>6 months). * Willingness to take oral desmopressin nightly for 8 weeks. * Parent/guardian able to monitor and report screen time and wet nights. * Written informed consent from parent/guardian and assent from child (if age-appropriate). Exclusion Criteria: * Secondary enuresis or non-monosymptomatic enuresis (daytime incontinence, urgency, frequency). * Known organic causes (e.g., diabetes mellitus, urinary tract anomalies, neurological disorders). * Current use of other enuresis treatments (alarms, anticholinergics, imipramine) within 4 weeks prior to enrollment. * Severe sleep disorders (e.g., obstructive sleep apnea) or psychiatric conditions affecting compliance. * Inability to comply with study procedures or follow-up.